Recent studies in novel therapy for metastatic sarcomas

Dejka M Steinert; Shreyaskumar R Patel

doi:10.1016/j.hoc.2005.03.002

Recent studies in novel therapy for metastatic sarcomas

Hematol Oncol Clin North Am. 2005 Jun;19(3):573-90, viii. doi: 10.1016/j.hoc.2005.03.002.

Authors

Dejka M Steinert¹, Shreyaskumar R Patel

Affiliation

¹ Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Unit 10, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

PMID: 15939198
DOI: 10.1016/j.hoc.2005.03.002

Abstract

Many new chemotherapeutic agents and targeted therapies are being studied in the treatment of metastatic soft tissue sarcomas (STSs). This article reviews results of recent clinical studies of gemcitabine, docetaxel, paclitaxel, ecteinascidin, 9-nitrocamptothecin, and pegylated liposomal doxorubicin, in patients who have STSs. The use of targeted therapy in STSs is an exciting, constantly changing field. The activity of imatinib mesylate, SU11248, everolimus, and bortezomib are summarized.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic
Humans
Sarcoma / drug therapy*
Sarcoma / secondary*

Substances

Antineoplastic Agents